PCM
FOLD

Prelude Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Prelude Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$1K – 2022
2019
Q3 		$1K Buy
+100
New +$1.08K ﹤0.01% 1636
2019
Q1 		– Sell
-50,000
Closed -$479K – 1906
2018
Q4 		$479K Buy
50,000
+3,300
+7% +$36.3K 0.03% 481
2018
Q3 		$565K Buy
46,700
+34,700
+289% +$485K 0.03% 495
2018
Q2 		$187K Sell
12,000
-6,100
-34% -$92.2K 0.01% 768
2018
Q1 		$272K Buy
18,100
+10,600
+141% +$161K 0.02% 607
2017
Q4 		$108K Buy
7,500
+1,000
+15% +$13.7K 0.01% 771
2017
Q3 		$98K Sell
6,500
-1,000
-13% -$13.2K 0.01% 883
2017
Q2 		$76K Buy
7,500
+3,000
+67% +$24.1K 0.01% 862
2017
Q1 		$32K Hold
4,500
– – ﹤0.01% 1170
2016
Q4 		$22K Sell
4,500
-3,600
-44% -$24.9K ﹤0.01% 1296
2016
Q3 		$60K Buy
8,100
+200
+3% +$1.35K 0.01% 990
2016
Q2 		$43K Buy
7,900
+3,900
+98% +$27.3K 0.01% 1066
2016
Q1 		$34K Sell
4,000
-5,100
-56% -$36.1K ﹤0.01% 1035
2015
Q4 		$88K Buy
9,100
+5,100
+128% +$46K 0.01% 859
2015
Q3 		$56K Sell
4,000
-4,800
-55% -$75.3K 0.01% 1024
2015
Q2 		$125K Sell
8,800
-4,500
-34% -$54.1K 0.02% 820
2015
Q1 		$145K Buy
13,300
+12,100
+1,008% +$107K 0.02% 831
2014
Q4 		$10K Buy
+1,200
New +$8.24K ﹤0.01% 1801

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Prelude Capital Management's FOLD Position: Q1 2026 in Review

Prelude Capital Management increased its Amicus Therapeutics (FOLD) stake by 83% in Q1 2026, buying an estimated $4.16M and bringing the position to 639,885 shares worth $9.25M. The position accounts for 0.71% of the portfolio, ranked #20.

Prelude Capital Management first reported a position in FOLD in Q3 2014 and has held it in 25 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Prelude Capital Management held 639,885 shares of Amicus Therapeutics worth $9.25M as of Q1 2026.
  • Prelude Capital Management bought 290,471 Amicus Therapeutics shares in Q1 2026, an estimated $4.16M.
  • Amicus Therapeutics made up 0.71% of Prelude Capital Management's portfolio in Q1 2026, its #20 holding.
  • Prelude Capital Management first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 25 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.